Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer

Medical Oncology

Volumn 20, Issue 4, 2003, Pages 355-362

  Han, Ji Youn ^a   Hong, Eun Kyung ^a   Choi, Byung Gil ^b   Park, Jin No ^c   Kim, Ki Won ^c   Kang, Jin Hyung ^c   Jin, Jong Youl ^c   Park, Suk Young ^c   Hong, Young Seon ^c   Lee, Kyung Shik ^c  

^a National Cancer Center   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c NONE

Author keywords

Bcl 2; Cisplatin; DR5; Gemcitabine

Indexed keywords

CASPASE 7; CISPLATIN; CYTOCHROME C; DEATH RECEPTOR 5; GEMCITABINE; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; THORAX RADIOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL RATE;

EID: 9144222021     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:4:355     Document Type: Article

References (28)

1. Sandler, A.B., et al. (2000). Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol 18:122-130.
2. Cardenal, F., et al. (1999). Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 17:12-18.
3. Crino, L., et al. (1999). Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17:3522-3530.
4. Huisman, C., et al. (2001). Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. Lung Cancer 33:261-215.
5. Yang, Z., et al. (2000). Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother. Pharmacol. 46:255-262.
6. Huang, P. and Plunkett, W. (1995). Induction of apoptosis by gemcitabine. Semin. Oncol. 22(4 Suppl. 11):1-25.
7. Igney, F.H. and Krammer, P.H. (2002). Death and anti-death: tumour resistance to apoptosis. Nature Rev. Cancer 2:277-288.
8. Houghton, J.A. (1999). Apoptosis and drug response. Curr. Opin. Oncol. 11:475-481.
9. Odoux, C., et al. (2002). TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int. J. Cancer 97:458-465.
10. Ibrahim, S.M., et al. (2001). Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23:72-79.
11. Park, W.S., et al. (2001). Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 121:1219-1225.
12. Lee, S.H., et al. (1999). Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59:5683-5686.
13. Zhang, X.D., et al. (2000). Differential localization and regulation of death and decoy receptors for TNP-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J. Immunol. 164:3961-3970.
14. Wu, G.S., et al. (1999). Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59:2770-2775.
15. Gibson, S.B., et al. (2000). Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell. Biol. 20:205-212.
16. Nimmanapalli, R., et al. (2001). Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61:759-763.
17. Liu, W., et al. (2001). Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am. J. Respir. Cell. Mol. Biol. 25:111-118.
18. Nagane, M., et al. (2000). Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60:847-853.
19. Miyashita, T. and Reed, J.C. (1992). bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:5407-5411.
20. Bold, R.J., Chandra, J. and McConkey, D.J. (1999). Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann. Surg. Oncol. 6:279-285.
21. Sun, S.Y., et al. (2001). Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem. Biophys. Res. Commun. 280:788-797.
22. de Almodovar, C.R., et al. (2001). The differential sensitivity of Bcl-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bcl-2 protein levels. Oncogene 20:7128-7133.
23. Han, J.Y., et al. (1999). The relationship between cisplatin-induced apoptosis & p53, bcl-2, and bax expression in human lung cancer cells. Kor. J. Intern. Med. 14:42-52.
24. Ozawa, F., et al. (2001). Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 163:71-81.
25. Katabami, M., et al. (1998). p53 and Bcl-2 expression in pneumoconiosis-related pre-cancerous lesions and lung cancers: frequent and preferential p53 expression in pneumoconiotic bronchiolar dysplasias. Int. J. Cancer 75:504-511.
26. Simon, R. (1998). Design, analysis, and reporting of cancer clinical trials, in Biopharmaceutical Statistics for Drug Development, (Peace, K.E., ed.), pp. 459-488, Dekker, New York.
27. Schiller, J.H., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346:92-98.
28. Kelly, K., et al. (2001). Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19:3210-3218.